Just musing here. IF the OnCarlytics/Blincyto trial yields great...

Just musing here. IF the OnCarlytics/Blincyto trial yields great outcome for the patients, ie CRs and strong PRs, would Amgen decides:

'Nope, we don't want anything to do with treating 90% of the solid cancer market'
or
'FECK! Let's BUY Imugene or BEG them to give us a deal'

Which is the most likely scenario? And I stress again, only IF the trial outcome is successful.

And then of course there is that OnCarlytics/Azer-cel trial. If is successful, then whoever comes after that to do a deal will literally have to go on their knees to beg IMU to throw a bit of bone over to them for IMU won't really need any of them anymore by then. In view of that, I believe if the above OnCarlytics/Blincyto successful scenario were to come to pass, I bet Amgen would not wait nor hesitate to ring IMU. In fact, they might panic if IMU did not pick up the phone quick enough

OK, musing over